Mary Kerr (NeRRe)
July 7, 2021 08:56 AM EDTUpdated 10:02 AM
Financing

Af­ter sell­ing its spin­out to Bay­er in a $875M-plus deal, NeRRe Ther­a­peu­tics grabs $28M for some 'un­fin­ished busi­ness'

Amber Tong

Some biotech CEOs find them­selves out of jobs fol­low­ing a buy­out. Not Mary Kerr.

In fact, af­ter Bay­er dished out $425 mil­lion in cash to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times